Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00589602 · OUTCOME

Number of Participants With Relapse-free Survival

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases · Source last updated 2017-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
after 7 years of follow up

What was measured

number of patients that were still alive and relapse free

Analysis population: All patients that received treatment

Groups in this outcome

T-Cell Depletion Transplant

peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg. cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day -5 and Day -4 tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
T-Cell Depletion Transplant12

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
T-Cell Depletion Transplant2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
number of patients that were still alive and relapse free
groups
  1. description
    peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg. cyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day -5 and Day -4 tacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation total-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days
    id
    OG000
    title
    T-Cell Depletion Transplant
param Type
NUMBER
population Description
All patients that received treatment
reporting Status
POSTED
time Frame
after 7 years of follow up
title
Number of Participants With Relapse-free Survival
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice